New Study: Intrathecal Umbilical Stem Cells + Transcutaneous Stimulation for Spinal Cord Injury
The neurorehabilitation hospital in Spain will investigate if allogeneic umbilical-derived stem cell therapy can help enhance recovery.
This new study will evaluate if intrathecal administration of Wharton’s jelly mesenchymal stem cells (WJ-MSCs), combined with transcutaneous spinal cord stimulation (tSCS) and intensive neurorehabilitation, is safe and feasible for individuals with chronic traumatic spinal cord injuries (SCI).
It’s sponsored by Institut Guttmann, a neurorehabilitation hospital in Spain. They will enroll 10 participants aged 16-70, classified as ASIA Impairment Scale grades A-C, who experienced cervical or thoracic SCI (levels C1-T12) between one and five years prior.
Stay Ahead in Regenerative Medicine
Thanks! Your signup has been saved.
Participants will receive three doses of cryopreserved allogeneic WJ-MSCs, each containing approximately 30 million viable cells, administered intrathecally at the L3-L4 spinal level at six-week intervals. Concurrently, subjects will undergo non-invasive tSCS and standardized neurorehabilitation. Researchers will primarily monitor safety by assessing treatment-emergent adverse events, neurological worsening (measured by changes in AIS grade), cerebrospinal fluid abnormalities, and procedure-related complications.
Secondary measures include evaluating changes in motor function through the AIS Motor Score, assessing voluntary muscle strength across 10 muscle groups over a 12-month period.
They expect to finish the trial in December of 2028.
Link to trial:
https://clinicaltrials.gov/study/NCT06981338
Similar stories
Wolwo Bio Subsidiary Receives Chinese Trial Authorization for Umbilical Cord Mesenchymal Stem Cell Therapy for Sepsis
New Trial – Phase II Umbilical-Cord Stem Cells for Amyotrophic Lateral Sclerosis
New Trial – Intranasal Stem Cells for Perinatal Brain Injury and Cerebral Palsy
Made Scientific Acquires Resilience’s 85K-Square-Foot Cell Therapy FacilityEditor’s Picks
Century Therapeutics Reports Sustained Glucose Control With iPSC-Derived Islets in Diabetic Mice, IND Soon
Inside Cellular Intelligence: The Zuck-Backed AI Company That Acquired Novo’s Parkinson’s Cell Therapy
Webinar: Scaling iPSC Therapies Without Scaling VariabilityOn-Demand
Aspen Neuroscience Publishes Preclinical Data on Parkinson’s iPSC-Derived Cell Therapy
